Danielle Cantey

Danielle brings a decade of experience shaping corporate narratives, navigating complex issues and crises, building meaningful media relationships, and guiding biotech companies through high-stakes milestones. She serves as a strategic advisor to investment firms and biotech companies across the drug development lifecycle helping companies articulate vision, navigate market-critical moments, and build trusted reputations with investors, media and key industry stakeholders.

Throughout her career, Danielle has led communications strategies for key inflection points including regulatory milestones, clinical data readouts, private and public financing events (including SPACs and IPOs), leadership transitions, and corporate restructurings. She is known for her ability to translate complex science into compelling narratives, shape clear and confident corporate positioning, and build strong relationships with top-tier biotech and healthcare reporters. Danielle is passionate about elevating the stories behind scientific innovation and supporting organizations that are driving meaningful impact for patients.

Through integrated communications programs, Danielle has supported a broad range of investigational therapies. Her experience spans multiple modalities – including cell and gene therapy, peptides, antibody-drug conjugates and small molecules – across a diverse set of therapeutic areas such as metabolic disease, oncology, neuropsychiatry, neurology, rare disease, and immunology.

Prior to joining LifeSci Communications, Danielle supported emerging and established biotech clients at Real Chemistry, Inizio Evoke, FGS Global and Ten Bridge Communications. She earned a B.S. in mass communication from Boston University.